Gastrointestinal disturbances and their management in miglustat-treated patients.
about
Diagnostic workup and management of patients with suspected Niemann-Pick type C diseaseNiemann-Pick disease treatment: a systematic review of clinical trialsDysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustatRecent advances in the diagnosis and treatment of niemann-pick disease type C in children: a guide to early diagnosis for the general pediatricianA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsMiglustat: a review of its use in Niemann-Pick disease type C.A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher diseaseIn vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4.Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study.Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution.Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority studySuccessful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case reportInfantile gangliosidoses: Mapping a timeline of clinical changes.Niemann-Pick type C: focus on the adolescent/adult onset form.Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.Long term differential consequences of miglustat therapy on intestinal disaccharidases.Effects of miglustat on stabilization of neurological disorder in niemann-pick disease type C: Iranian pediatric case series.The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.Pharmacotherapy of Gaucher Disease: Current and Future Options.Gaucher diseaseMiglustat in Niemann-Pick disease type C patients: a review
P2860
Q26748586-DF6BA261-A024-4381-83C1-BF26BF4B840BQ26774861-2CDF696F-984A-4090-9398-34A05ED2EC32Q26825102-07C86AB3-CAFD-4803-A952-C7DE4E30A169Q28082532-D6DAD926-9911-4F64-983F-F713324C741CQ30235844-3162DB28-41E7-400E-84C9-27221F92D5C1Q33460275-FFDC9272-CE38-49B2-8281-05BE905B1C62Q33465330-05E9F811-267C-4881-A4A8-E58F17CFC549Q33568024-C2FDEFF0-9509-48CA-A485-9025BA2966E5Q34168892-6F4A870A-2D37-4F8C-A1B8-30D0C1BD823AQ35191986-26BDD289-CC86-4A79-B272-5B57571137B1Q35536435-D79E2516-15F8-492B-80C9-B104BB2A0B85Q35710895-D3C02561-0D3B-4D79-8681-B90D78024CD9Q35764898-40525A93-1C66-4567-A6A4-D536B61AF4EDQ35806919-9C03AB6F-320D-44D6-AD1F-3449C69C7904Q36299871-213AB73D-2C69-4C8D-9FE6-22288FA76BD7Q36556379-B7E99EDB-6E10-4910-8DCA-0FA3B89404B0Q37400927-8E361A5E-97FE-4367-973B-9E21CB5D9EAEQ37595782-36A2FF2B-70F3-4BFA-892A-740B23773608Q38687184-0CC17785-0B4A-45ED-B629-DD4C33FD7FC1Q38783095-D3FD4BED-313E-4067-961C-56EF387C815EQ40479802-DB0927D2-919A-471D-B0EB-DC0A01D8B94AQ41471477-AC57F463-76DE-4853-81DF-8851A7F783B4Q43511609-2DFFD33C-58F4-492E-AD7E-665BEF8C9844Q50358080-F5436830-AD70-4B76-833C-414FC9D718D4Q50604259-0AD4EB02-F4B2-4E67-BA11-1B919509ED0CQ55062298-8292CE42-F8D0-4863-823C-31D000655A15Q56338451-4129B99D-7051-4CC8-BFBA-5AA518979E85Q58778074-A757BC68-FA30-44D9-A5DB-C4C94AB077C7
P2860
Gastrointestinal disturbances and their management in miglustat-treated patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Gastrointestinal disturbances and their management in miglustat-treated patients.
@ast
Gastrointestinal disturbances and their management in miglustat-treated patients.
@en
type
label
Gastrointestinal disturbances and their management in miglustat-treated patients.
@ast
Gastrointestinal disturbances and their management in miglustat-treated patients.
@en
prefLabel
Gastrointestinal disturbances and their management in miglustat-treated patients.
@ast
Gastrointestinal disturbances and their management in miglustat-treated patients.
@en
P2093
P2860
P1476
Gastrointestinal disturbances and their management in miglustat-treated patients.
@en
P2093
Alberto Burlina
Chris J Hendriksz
David J Kuter
Gregory M Pastores
Nadia Belmatoug
Pilar Giraldo
P2860
P2888
P304
P356
10.1007/S10545-011-9368-7
P50
P577
2011-07-21T00:00:00Z
P6179
1047941320